Manuscripts and Publications

Filters: Author is Han, Meilan K  [Clear All Filters]
2014
O'Neal WK, Anderson W, Basta PV, Carretta EE, Doerschuk CM, R Barr G, Bleecker ER, Christenson SA, Curtis JL, Han MK et al..  2014.  Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study.. J Transl Med. 12:9.
Smith BM, Hoffman EA, Rabinowitz D, Bleecker E, Christenson S, Couper D, Donohue KM, Han MK, Hansel NN, Kanner RE et al..  2014.  Comparison of spatially matched airways reveals thinner airway walls in COPD. The Multi-Ethnic Study of Atherosclerosis (MESA) COPD Study and the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS).. Thorax. 69(11):987-96.
Putcha N, Puhan MA, M Drummond B, Han MK, Regan EA, Hanania NA, Martinez CH, Foreman M, Bhatt SP, Make B et al..  2014.  A simplified score to quantify comorbidity in COPD.. PLoS One. 9(12):e114438.
2015
Boes JL, Hoff BA, Bule M, Johnson TD, Rehemtulla A, Chamberlain R, Hoffman EA, Kazerooni EA, Martinez FJ, Han MK et al..  2015.  Parametric response mapping monitors temporal changes on lung CT scans in the subpopulations and intermediate outcome measures in COPD Study (SPIROMICS).. Acad Radiol. 22(2):186-94.
2016
Martinez CH, Diaz AA, Parulekar AD, Rennard SI, Kanner RE, Hansel NN, Couper D, Holm KE, Hoth KF, Curtis JL et al..  2016.  Age-Related Differences in Health-Related Quality of Life in COPD: An Analysis of the COPDGene and SPIROMICS Cohorts.. Chest. 149(4):927-35.
Woodruff PG, R Barr G, Bleecker E, Christenson SA, Couper D, Curtis JL, Gouskova NA, Hansel NN, Hoffman EA, Kanner RE et al..  2016.  Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function.. N Engl J Med. 374(19):1811-21.
Sun W, Kechris K, Jacobson S, M Drummond B, Hawkins GA, Yang J, Chen T-H, Quibrera PMiguel, Anderson W, R Barr G et al..  2016.  Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD.. PLoS Genet. 12(8):e1006011.
Guo J, Wang C, Chan K-S, Jin D, Saha PK, Sieren JP, Barr RG, Han MK, Kazerooni E, Cooper CB et al..  2016.  A controlled statistical study to assess measurement variability as a function of test object position and configuration for automated surveillance in a multicenter longitudinal COPD study (SPIROMICS).. Med Phys. 43(5):2598.
Sieren JP, Newell JD, R Barr G, Bleecker ER, Burnette N, Carretta EE, Couper D, Goldin J, Guo J, Han MK et al..  2016.  SPIROMICS Protocol for Multicenter Quantitative Computed Tomography to Phenotype the Lungs.. Am J Respir Crit Care Med. 194(7):794-806.
Putcha N, R Barr G, Han MK, Woodruff PG, Bleecker ER, Kanner RE, Martinez FJ, Smith BM, Tashkin DP, Bowler RP et al..  2016.  Understanding the impact of second-hand smoke exposure on clinical outcomes in participants with COPD in the SPIROMICS cohort.. Thorax. 71:411-420.
2017
Martinez CH, Diaz AA, Meldrum C, Curtis JL, Cooper CB, Pirozzi C, Kanner RE, Paine R, Woodruff PG, Bleecker ER et al..  2017.  Age and Small Airway Imaging Abnormalities in Subjects with and without Airflow Obstruction in SPIROMICS.. Am J Respir Crit Care Med. 195(4):464-472.
Kesimer M, Ford AA, Ceppe A, Radicioni G, Cao R, C Davis W, Doerschuk CM, Alexis NE, Anderson WH, Henderson AG et al..  2017.  Airway Mucin Concentration as a Marker of Chronic Bronchitis.. N Engl J Med. 377(10):911-922.
Hastie AT, Martinez FJ, Curtis JL, Doerschuk CM, Hansel NN, Christenson S, Putcha N, Ortega VE, Li X, R Barr G et al..  2017.  Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort.. Lancet Respir Med. 5(12):956-967.
Keene JD, Jacobson S, Kechris K, Kinney GL, Foreman MG, Doerschuk CM, Make BJ, Curtis JL, Rennard SI, R Barr G et al..  2017.  Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts.. Am J Respir Crit Care Med. 195(4):473-481.
Fernández-Baldera A, Hatt CR, Murray S, Hoffman EA, Kazerooni EA, Martinez FJ, Han MK, Galbán CJ.  2017.  Correcting Nonpathological Variation in Longitudinal Parametric Response Maps of CT Scans in COPD Subjects: SPIROMICS.. Tomography. 3(3):138-145.
Bowler RP, Hansel NN, Jacobson S, R Barr G, Make BJ, Han MK, O'Neal WK, Oelsner EC, Casaburi R, Barjaktarevic I et al..  2017.  Electronic Cigarette Use in US Adults at Risk for or with COPD: Analysis from Two Observational Cohorts.. J Gen Intern Med. 32(12):1315-1322.
Han MK, Quibrera PM, Carretta EE, R Barr G, Bleecker ER, Bowler RP, Cooper CB, Comellas A, Couper DJ, Curtis JL et al..  2017.  Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.. Lancet Respir Med. 5(8):619-626.
Martinez CH, Murray S, R Barr G, Bleecker E, Bowler RP, Christenson SA, Comellas AP, Cooper CB, Couper D, Criner GJ et al..  2017.  Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes. An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort.. Ann Am Thorac Soc. 14(5):636-642.
Hansel NN, Paulin LM, Amanda G, Roger P, Alexis NE, Fan V, Bleecker E, Bowler RP, Comellas AP, Dransfield MT et al..  2017.  Subpopulations and Intermediate Outcomes in COPD (SPIROMICS) Air Pollution Study Design. BJM Open Respiratory Research. 4(1)
Anderson WH, Ha JWook, Couper DJ, O'Neal WK, R Barr G, Bleecker ER, Carretta EE, Cooper CB, Doerschuk CM, M Drummond B et al..  2017.  Variability in objective and subjective measures affects baseline values in studies of patients with COPD.. PLoS One. 12(9):e0184606.
2018
Martinez CH, Li SX, Hirzel AJ, Stolberg VR, Alexis NE, R Barr G, Bleecker ER, Carretta EE, Christenson SA, Cooper CB et al..  2018.  Alveolar eosinophilia in current smokers with chronic obstructive pulmonary disease in the SPIROMICS cohort.. J Allergy Clin Immunol. 141(1):429-432.
Putcha N, Fawzy A, Paul GG, Lambert AA, Psoter KJ, Sidhaye VK, Woo J, J Wells M, Labaki WW, Doerschuk CM et al..  2018.  Anemia and Adverse Outcomes in a Chronic Obstructive Pulmonary Disease Population with a High Burden of Comorbidities. An Analysis from SPIROMICS.. Ann Am Thorac Soc. 15(6):710-717.
Han MK, Tayob N, Murray S, Woodruff PG, Curtis JL, Kim V, Criner G, Galbán CJ, Ross BD, Hoffman EA et al..  2018.  Association between Emphysema and Chronic Obstructive Pulmonary Disease Outcomes in the COPDGene and SPIROMICS Cohorts: A Post Hoc Analysis of Two Clinical Trials.. Am J Respir Crit Care Med. 198(2):265-267.
Fawzy A, Putcha N, Paulin LM, Aaron CP, Labaki WW, Han MK, Wise RA, Kanner RE, Bowler RP, R Barr G et al..  2018.  Association of thrombocytosis with COPD morbidity: the SPIROMICS and COPDGene cohorts.. Respir Res. 19(1):20.
Bhatt SP, Nath HP, Kim Y-I, Ramachandran R, Watts JR, Terry NLJ, Sonavane S, Deshmane SP, Woodruff PG, Oelsner EC et al..  2018.  Centrilobular emphysema and coronary artery calcification: mediation analysis in the SPIROMICS cohort.. Respir Res. 19(1):257.

Pages